Provention Bio Inc (NASDAQ:PRVB) Director Anthony Digiandomenico purchased 5,000 shares of the firm’s stock in a transaction on Friday, November 30th. The shares were purchased at an average price of $2.45 per share, for a total transaction of $12,250.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Anthony Digiandomenico also recently made the following trade(s):
- On Monday, November 26th, Anthony Digiandomenico purchased 10,000 shares of Provention Bio stock. The shares were purchased at an average price of $2.65 per share, for a total transaction of $26,500.00.
Shares of NASDAQ PRVB traded up $0.07 during mid-day trading on Thursday, hitting $2.64. The company had a trading volume of 883 shares, compared to its average volume of 38,948. Provention Bio Inc has a 1-year low of $2.02 and a 1-year high of $8.00.
Provention Bio (NASDAQ:PRVB) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.17) earnings per share (EPS) for the quarter.
A hedge fund recently bought a new stake in Provention Bio stock. Dean Capital Investments Management LLC acquired a new stake in Provention Bio Inc (NASDAQ:PRVB) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 40,950 shares of the company’s stock, valued at approximately $164,000. Dean Capital Investments Management LLC owned approximately 0.12% of Provention Bio at the end of the most recent quarter. Institutional investors and hedge funds own 2.51% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Anthony Digiandomenico Buys 5,000 Shares of Provention Bio Inc (PRVB) Stock” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/12/06/anthony-digiandomenico-buys-5000-shares-of-provention-bio-inc-prvb-stock.html.
About Provention Bio
Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.
Further Reading: Asset Allocation, Balancing Your Investments
Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.